Bladder Cancer

Atezolizumab Could Be Start of “Seismic Shift”  in Metastatic Bladder Cancer Therapy

Preliminary results also showed encouraging overall survival data, said Arjun V. Balar, MD, Co-Leader of the Genitourinary Cancers Program, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, who presented the results.

Read More ›

The study included 2 main comparisons of adjuvant chemoradiotherapy versus radiation and adjuvant chemoradiotherapy versus chemotherapy alone. The 3-year disease-free survival rate was 68% for adjuvant chemoradiotherapy versus 63% for radiation alone, but this 5% difference was not statistically significant. The 3-year disease-free survival rate in the second comparison was 68% for chemoradiotherapy versus 56% for chemotherapy alone, a numerical trend toward improved survival with chemoradiotherapy.

Read More ›

In the era of personalized medicine, identifying patients with cancer who will benefit most from a specific treatment is the Holy Grail. Currently, there is no test to identify effective chemotherapy before administering treatment. Read More ›

It is valid to predict survival using tumor stage after neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC), said Peter Black, MD, Senior Research Scientist, Vancouver Prostate Centre, British Columbia, Canada. Read More ›

Subscribe to
Rheumatology Practice Management

Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or weekly e‑Newsletter.

I'd like to receive: